AstraZeneca Logo

  • Introduction
  • Biomarker Testing in Lung Cancer
  • Technical Considerations
  • iD Podcasts
  • Resources & Links
  • FAQs
iD.Lung Logo
menu
 
 

iD Podcast

Listen to short, insightful podcast episodes
delivered by expert pathologists

The AstraZeneca-sponsored iD Podcasts aim to discuss the latest clinical and diagnostic advancements in lung cancer. Each episode has a supporting PDF document, which contains a written summary of key takeaways and additional materials for further reading.

iD Podcasts : Testing Cytology Samples For PD-L1
iD Podcasts : Tissue Stewardship
iD Podcasts : Options For Rapid Turnaround NSCLC Testing
iD Podcasts : PD-L1 Assay Harmonisation

ABBREVIATIONS:
NSCLC, non-small cell lung cancer; PD-L1, programmed cell death ligand-1

iD.Lung.com

  • Introduction
  • Biomarker Testing in Lung Cancer
  • Technical Considerations
  • iD Podcasts
  • Resources & Links
  • FAQs
  • Contact Us
  • Legal Notice
  • Privacy Policy
  • Cookies
AstraZeneca Logo

©AstraZeneca 2024
FOR HEALTHCARE PROFESSIONAL USE ONLY
Veeva Document ID: Z4-60052 | Date of preparation: September 2024

Welcome to the iD LUNG website

Access to the iD Lung website is for non-US healthcare professionals, and is of particular relevance for medical oncologists, pathologists and the surgical team.

By clicking on the link below, you declare and confirm that you are a non-US healthcare professional.

Access the site

Patients or members of the public

This website is intended for healthcare professionals only. Please speak to your healthcare provider if you require further information on lung cancer.

Media

If you are a member of the press, please contact the AstraZeneca Press Office.

Content

The content of this website is not exhaustive and should not be used as a substitute for the information provided by the manufacturers of the diagnostic assays. For specific guidance on testing protocols, please consult the package insert provided with each diagnostic test.